Princess Margaret Hospital/Ontario Cancer Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schuh, Andre
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Hourglass Jun 2025 - Jun 2025 : Updated results and longer follow-up data for r/r KMT2Ar acute leukemia
Hourglass Jun 2025 - Jun 2025 : Data from P1 portion for r/r NUP98r acute leukemias
Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
Bratman, Scott
EVADER, NCT03822897: De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting
2
103
Canada
Radiation, No available, Cisplatin
Canadian Cancer Trials Group
Oropharyngeal Cancer
06/24
06/25
PRE-MERIDIAN, NCT04599309: Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
N/A
35
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
03/23
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schuh, Andre
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Hourglass Jun 2025 - Jun 2025 : Updated results and longer follow-up data for r/r KMT2Ar acute leukemia
Hourglass Jun 2025 - Jun 2025 : Data from P1 portion for r/r NUP98r acute leukemias
Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
Bratman, Scott
EVADER, NCT03822897: De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting
2
103
Canada
Radiation, No available, Cisplatin
Canadian Cancer Trials Group
Oropharyngeal Cancer
06/24
06/25
PRE-MERIDIAN, NCT04599309: Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
N/A
35
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
03/23
12/24

Download Options